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Abstract
Background: To investigate perceptions and attitude to prescribe Pre-Exposure Prophylaxis (PrEP) among HIV specialists.
Methods: A questionnaire developed through a Focus Group and literature review was administered to a convenience
sample of HIV specialists during educational courses in two Regions and an online survey in February-May 2012.
Participants were classified as having a positive or negative attitude according to their willingness to prescribe PrEP.
Demographic and working information, experience with HIV-infected patients, information and provision of antiretrovirals
to uninfected persons, self-reported knowledge, perceptions and concerns regarding PrEP were assessed. The association
between a different attitude towards PrEP prescription and selected characteristics was assessed through univariate and
multivariate regression analysis.
Results: Of 311 specialists, 70% would prescribe PrEP, mainly to serodiscordant partners (64%) but also to people at
ongoing, high risk of HIV infection (56%); 66% advocated public support of costs. A negative attitude towards PrEP was
significantly associated with lack of provision of information on, and prescription of, antiretroviral post-exposure
prophylaxis; specialists with a negative attitude believed behavioural interventions to be more effective than PrEP and
were more concerned about toxicity. Overall, 90% of specialists disagreed regarding a lack of time for engaging in
prevention counselling and PrEP monitoring; 79% would welcome formal guidelines, while those with a negative attitude
did not consider this advisable.
Conclusions: Although conflicting attitudes appear evident, most specialists seem to be willing, with guidance from
normative bodies, to promote PrEP within multiple prevention strategies among vulnerable populations. More scientific
evidence regarding effectiveness could overcome resistance.
Keywords: HIV pre-exposure prophylaxis, Antiretroviral drugs, HIV prevention, HIV healthcare providers, Health
knowledge, Attitudes, Practice
Background
The impressive improvements in the treatability of HIV
infection have not been paralleled by similarly remarkable
improvements in the effectiveness of HIV prevention
strategies; therefore, more successful approaches are ur-
gently needed.
In the last years, the emphasis in the field of research on
prevention has shifted to the development of combination
prevention packages in which structural, behavioural, and
biomedical interventions are implemented concurrently [1].
Biomedical prevention strategies include using antire-
trovirals (ARV) treatment as prevention (TasP), i.e. treating
HIV-infected patients, regardless of clinical status, to curb
transmission. However, gaps in the continuum from HIV
diagnosis, through linkage to care, uptake and adherence to
antiretroviral therapy, are substantially limiting its actual im-
pact [2,3].
More recently, the use of ARV for pre-exposure prophy-
laxis (PrEP) among high-risk persons without HIV is emer-
ging as one additional strategy to curtail the HIV epidemic.
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While there have been significant studies suggesting
the high potential efficacy of PrEP, although strongly re-
lated to adherence [4-7], others were halted early due to
no difference between placebo and PrEP arms [8-10],
again perhaps due to difficulties with adherence.
In any case, several questions arise about PrEP delivery
in the real world. In particular, it seems necessary to
understand the point of view of the providers on the ac-
tual implementation of PrEP in their clinical context, as
well as to investigate how PrEP will be perceived by the
communities of individuals at high risk.
In Italy, the care for HIV-infected patients, counseling,
and testing were almost exclusively carried out by spe-
cialists in Infectious Diseases; the same is true for the
provision of ARV. In addition, these HIV specialists have
built up extensive expertise in prescribing ARV for post-
exposure prophylaxis (PEP) to prevent occupational and
sexual acquisition of HIV infection [11,12].
Although PrEP has not been regulated or tested at a
national level so far, HIV specialists are likely to be the
first prescribers of PrEP [13], and might have patients
who require it. We therefore decided to investigate per-
ceptions regarding PrEP through a survey of HIV spe-
cialists, to assess their attitude to prescribe and monitor
PrEP use, and to identify factors predictive of a positive
attitude towards PrEP prescription.
The survey was conducted between February and May
2012, when the results of CAPRISA and iPREX trials had
been published [4,5], Partners and TDF2 studies had been
presented [6,7], and the inconsistent results of FEM-PrEP
and VOICE studies were already available [8,10].
Methods
Participants, focus group and survey instrument
To develop the questionnaire, a focus group [14] discussing
PrEP potential impact on HIV prevention was conducted in
January 2012 at the “Lazzaro Spallanzani” National Institute
for Infectious Diseases in Rome. On the basis of the existent
literature on PrEP, a Focus Group Interview Guide was de-
veloped focusing on the following main areas: knowledge on
PrEP trials, ideal target populations, attitudes and concerns
about this potential new biomedical HIV prevention tool.
A convenience sample of 10 internal HIV specialists
voluntarily participated in the focus group. The focus
group was guided by a physician (V.P.) and a psycholo-
gist (A.P.), lasted 2 h30 and was digitally audio-recorded,
verbally-transcribed, analysed, and the main themes
were extracted.
Then the Fenway Institute group was contacted [15],
and part of their original survey tool, kindly provided,
was incorporated in the first version of the questionnaire
after adaptation.
In February 2012, a pilot study was conducted admin-
istering the questionnaire to HIV specialists before the
beginning of an HIV educational course, dedicated to
PEP and PrEP, in Tuscany.
After revision, which determined the addition of
four items, the questionnaire was administered to
other specialists in Tuscany, and in Latium before
analogous courses; denominators in the analysis may
vary accordingly.
In May the survey was put online through LimeSurvey®,
and an e-mail invitation was sent to contacts included in a
professional listserve of the Italian Society of Infectious
and Tropical Diseases, soliciting the specialists to partici-
pate in the project through the Web link.
A copy of the questionnaire is attached to this article
(Additional file 1).
The study was approved by the National Institute of
Health (Istituto Superiore di Sanità), and is in compli-
ance with the World Medical Association Declaration of
Helsinki.
Participation was voluntary, no financial incentive was
offered. Both the paper-and-pencil and online surveys
were completely anonymous, did not include personal/
sensitive data, and according to the Italian legislation,
did not specifically require to be approved by an Ethics
Committee.
Measures and variable definitions
The specialists were asked if they would ever prescribe
PrEP, and to whom, among a number of possible target
populations. Participants were classified as having a
positive attitude if they would consider prescribing PrEP
at least in some cases, or a negative attitude if they
would not prescribe PrEP in any case.
Demographic and working information included gen-
der, age class, length of service, workplace (non teaching
hospital or university hospital/research institute) and
prevailing activity (ward/inpatients, outpatient clinic/day
hospital).
Experience was investigated through the years of work
with HIV patients, the total number of HIV patients
cared for and the number of HIV tests prescribed in the
last month.
PEP or PrEP prescription to HIV-uninfected persons,
and pre-emptive provision of information on PEP to pa-
tients were investigated.
Participants were asked to self-evaluate their own
knowledge regarding PrEP.
Perceptions regarding PrEP were assessed through
participants’ agreement with a series of statements.
Whether participants would ascribe the costs of PrEP to
the National Health System (NHS) was also asked.
Moreover, after the pilot study, an hypothetical scenario
of “a serodiscordant couple where the HIV-infected part-
ner is not eligible for starting ARV according to national
guidelines”, was presented and participants were asked
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about their attitude towards counselling on safe sex only
vs. the additional use of ARV to protect the uninfected
partner.
Finally, participants were asked whether they would con-
sider appropriate that formal guidelines were issued to
guide PrEP prescription or a clinical trial started in which
to enrol patients.
Statistical analysis
The association between a positive attitude towards PrEP
prescription and selected characteristics was assessed by
odds ratio (OR) and their 95% confidence intervals (CI). A
multivariable logistic regression analysis was conducted to
examine the association between the set of significant bivari-
ate variables and positive attitude to PrEP; the adjusted OR
(MLR-OR) were assessed selecting, through backward elim-
ination (p > 0.20 as drop-out criteria) for the final model, all
those variables found to be significantly (p < 0.25) associated
with the outcome at the univariate analysis forcing age and
gender; the Hosmer-Lemeshow goodness of fit test was used
to assess model fit [16]. Data management and analysis




Most focus group participants reported a “not detailed”
knowledge about the results of published PrEP trials,
and expressed concerns regarding PrEP use. The main
concerns that emerged were: duration of use, side effects
and long term toxicities; ARV resistance; a possible in-
crease in sexually transmitted infections (STI); and the
problem of monitoring adherence.
The high costs of drugs to be used for PrEP in HIV
negative individuals and the possible competition with
the availability of funding for ARV treatment of infected
persons and for other preventive measures such as infor-
mation campaigns, were considered difficult-to-resolve
ethical issues.
The specialists did not find an agreement on PrEP tar-
get populations. The majority agreed to consider PrEP in
case of stable serodiscordant couples who wish to con-
ceive, in particular when the HIV negative partner is the
woman, while they would be more careful in offering
PrEP to individuals who report high-risk sexual beha-
viours, mainly for the fear of sexual disinhibition.
Finally, participants expressed the need for institutional
recommendations, and their willingness to participate in
PrEP trials.
Study population
The questionnaire was returned by 311 physicians (overall
response rate 40%), 40% of whom completed the online
survey.
Thirty per cent of specialists (n = 95) would not pre-
scribe PrEP in any case. Of the remaining 216, 81%
would prescribe it to high-risk subjects in some circum-
stances, and 93% to serodiscordant partners. Main target
populations were men who have sex with men (MSM)
not using condoms (55%), and serodiscordant indi-
viduals exposed to a viraemic partner (45%); PrEP to
women for conception, regardless of the viral load of
their partner, accounted for 71% (Table 1).
Demographic and working characteristics of the study
population, experience with HIV-infected patients, prac-
tice and knowledge, overall and according to the attitude
towards PrEP prescription, are shown in Table 2.
The majority of the respondents were males, aged
>50 years, working in non-teaching hospitals, with
inpatients, for more than 20 years.
Most participants had experience of the use of ARV in
HIV negative persons (255, 82%); 85% had prescribed
less than 20 HIV tests in the last month.
Overall, self-evaluation of PrEP knowledge was repor-
ted as at least sufficient in 69% of cases. At univariate
analysis, no differences were found between specialists
with a positive or negative attitude towards PrEP pre-
scription according to demographic characteristics,
working experience, experience with HIV-infected pa-
tients, or self-reported knowledge.
A positive attitude was more frequent among those
who participated in the HIV educational courses, had
prescribed ARV to negative individuals to prevent HIV
infection, and used to inform their patients previously
on PEP. All these factors remained significantly associ-
ated with a positive attitude at multivariate analysis
(Table 2). The model demonstrated adequate goodness
of fit, Hosmer-Lemeshow χ28 = 10.195, p = 0.252, and
accounted for 17.2% of the variance.
Participants’ perception of PrEP and their main con-
cerns, overall and according to attitude towards prescrip-
tion, are shown in Table 3.
Regardless of their attitude, the large majority of respon-
dents agreed that encouraging access to HIV testing and
care, and behavioural interventions, are more effective
(91% and 74%, respectively) and safer (89%), than PrEP;
regarding PrEP possible effect on testing frequency, re-
spondents split evenly.
Main concerns were, in order: efficacy, costs, in-
crease in risk behaviours and STI, side effects, risk of
drug resistance and adherence. In addition, 70% of
HIV specialists felt uncomfortable in prescribing ARV
for new indications in absence of clear evidence of ef-
fectiveness and safety, while 90% disagreed to lack
time for engaging in prevention counselling and PrEP
monitoring.
Regarding prescription barriers, specialists who would
prescribe PrEP are less concerned by potential toxicity
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and use of drugs for new indications (OR 2.39 and 2.01,
respectively); moreover, they are more likely to disagree
that behavioural interventions could be more effective
than PrEP (OR 3.78), or that PrEP could lead to a de-
creased attitude to test regularly (OR 1.63).
Overall, most respondents believed that NHS should sus-
tain PrEP costs: entirely, in all (28%) or selected (9%) cases
(i.e. conception), or partially, based on patient’s income
(29%). Of the remaining, 31% would charge the patient,
and 3% did not answer. Specialists who would prescribe
PrEP are more likely to support NHS participation in cov-
ering PrEP costs (OR 4.63; 95% CI 2.74-7.84). Of the two
items not included in the pilot session (denominator = 279
specialists), in the hypothetical scenario, of 271 respon-
dents 55% would choose only counselling on safe sex to
protect the uninfected partner, while 27% would add ARV
to the infected partner, 8% PrEP to the negative partner,
and 10% both.
Those with a positive attitude towards PrEP prescrip-
tion are definitely more likely to add PrEP, alone or in
combination with TasP, to prevent transmission (OR
4.46; 95% CI 1.78-11.16). As for the framework for PrEP
prescription, 79% considered appropriate the issue of
formal guidelines (not recommended 11%; 10% did not
answer), and 60% the start of a multicenter trial (not
recommended 22%; 18% did not answer). Those who
would prescribe PrEP are more prone to provide it
within the framework of a multicenter trial (OR 3.95;
95% CI 2.14-7.30; p < 0.001) and national/international
PrEP guidelines (OR 3.37; 95% CI 1.51-7.51; p = 0.003).
Discussion
In our survey, despite the multiple challenges identified,
there was a prevalent positive attitude of HIV specialists
towards PrEP prescription. Indeed, 70% of respondents
would offer PrEP, mainly to serodiscordant partners (64%),
especially women and MSM engaged with viraemic part-
ners, but also (56%) to people at ongoing, high risk of HIV
infection, primarily MSM, persons with STI and sex
workers not using condoms.
This correlates with the current epidemic pattern in
Italy, where some 4000–10000 (according to the differ-
ent models and data sources) new HIV infections are es-
timated to occur yearly: the highest estimated number of
recent infections is among MSM [17,18], and the highest
HIV prevalences have been observed in MSM, persons
with a current STI, and sex workers [19].
Regardless of their attitude, respondents expressed the
concern that widespread access to PrEP could lead to an
increased incidence of HIV and STI among at-risk popu-
lations, unintended toxicity and the emergence of resist-
ant strains, consistently with other studies [13,15,20].
However, only toxicity concerns were significantly more
frequent among specialists showing a negative attitude
towards PrEP. As for financial sustainability, although
deemed too expensive, most specialists advocated NHS
support of PrEP costs to ensure equity of access, consist-
ently with other studies where healthcare providers rec-
ognized cost as a major barrier for patients [13], and
wished public programmes to pay for PrEP if patients
cannot afford it [15].
Currently, PrEP is considered cost-effective when tar-
geted to high-risk populations with an annual incidence
>2% [21], as evidenced for MSM in Italy [22]; further
targeting based on risk factors (younger age, number of
annual partners, not being tested for HIV annually)
could help reducing PrEP financial impact.
Table 1 Attitudes towards pre-exposure prophylaxis
(PrEP) prescription among 311 HIV specialists
Based on the available evidence, do you think PrEP should be




Participants who think that PrEP should be offered (N = 216)
Offer PrEP to some groups of people at higher risk:a




N (%) N (%) N (%)
Men who have sex
with men (MSM)




90 (41.7) 35 (16.2) 125 (57.9)
Persons with
multiple partners
91 (42.1) 40 (18.5) 131 (60.6)
Sex workers/
Transactional sex
84 (38.8) 47 (21.8) 131 (60.6)
Respondents 174 (80.6)




N (%) N (%) N (%)
Men in heterosexual
couples…




98 (45.4) 73 (33.8) 171 (79.2)
Men in MSM
couples…
97 (44.9) 73 (33.8) 170 (78.7)
Women for
conception…
71 (32.8) 82 (38.0) 153 (70.8)
Men for
conception…
72 (33.3) 60 (27.8) 132 (61.1)
Respondents 200 (92.6)
a Percentages may exceed 100% as participants checked all that applied.
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Table 2 Factors associated with positive attitude towards PrEP prescription among HIV specialists
Attitude towards PrEP prescription Total
(N = 311)
Odds-ratio for positive attitude towards
PrEP prescription
Positive (N = 216) Negative (N = 95)
N (%) N (%) N (%) OR (95% CI) MLR-OR (95% CI)
Demographic characteristics and work history
Gender
Male 122 (56.5) 52 (54.7) 174 (55.9) 1 1
Female 94 (43.5) 43 (45.3) 137 (44.1) 0.93 (0.57-1.51) 0.85 (0.50-1.45)
Age Class
≤40 33 (15.3) 18 (18.9) 51 (16.4) 1 1
41-50 51 (23.6) 26 (27.4) 77 (24.8) 1.07 (0.51-2.25) 0.68 (0.30-1.56)
>50 132 (61.1) 51 (53.7) 183 (58.8) 1.41 (0.73-2.73) 1.07 (0.51-2.25)
Length of service (years)
< 10 35 (16.2) 20 (21.1) 55 (17.7) 1
10-19 71 (32.9) 35 (36.8) 106 (34.1) 1.16 (0.59-2.29)
> = 20 110 (50.9) 40 (42.1) 150 (48.2) 1.57 (0.81-3.03)
Workplace
Non teaching hospital 129 (59.7) 58 (61.1) 187 (60.1) 1
University/Research institute 87 (40.3) 37 (38.9) 124(39.9) 1.06 (0.65-1.73)
Prevailing activity
Ward/Inpatients 116 (53.7) 53 (55.8) 169 (54.3) 1
Outpatient clinic/Day hospital 100 (46.3) 42 (44.2) 142 (45.7) 1.09 (0.67-1.77)
Survey
Online Survey 69 (31.9) 55 (57.9) 124 (39.9) 1 1
Regional HIV education 147 (68.1) 40 (42.1) 187 (60.1) 2.93 (1.78-4.82) 3.25 (1.79-5.91)
Participants’ experience with HIV-infected patients
Onset of activity with HIV patients
HAART era 57 (26.4) 34 (35.8) 91 (29.3) 1
Pre-HAART era 159 (73.6) 61 (64.2) 220 (70.7) 1.55 (0.93-2.61)
HIV-infected persons currently followed
< =5 45 (20.8) 19 (20.0) 64 (20.6) 1
6-50 61 (28.2) 28 (29.5) 89 (28.6) 0.92 (0.46-1.85)
>50 110 (50.9) 48 (50.5) 158 (50.8) 0.97 (0.51-1.82)
HIV tests prescribed in the last month
< =5 109 (50.5) 46 (48.4) 155 (49.8) 1
6-20 77 (35.6) 33 (34.7) 110 (35.4) 0.98 (0.58-1.68)
>20 30 (13.9) 16 (16.8) 46 (14.8) 0.79 (0.39-1.59)
Practice
Antiretrovirals prescription to HIV negative individuals
No 26 (12.0) 30 (31.6) 56 (18.0) 1 1
Yes 190 (88.0) 65 (68.4) 255 (82.0) 3.37 (1.86-6.12) 2.43 (1.29-4.61)
Pre-emptive information on Post-Exposure Prophylaxis
No 65 (30.1) 44 (46.3) 109 (35,0) 1 1
Yes 151 (69.9) 51 (53.7) 202 (65,0) 2.00 (1.22-3.30) 1.72 (1.01-2.92)
Knowledge
Self-evaluation of PrEP knowledge
Poor 73 (33.8) 27 (28.4) 100 (32.1) 1 1
Sufficient 72 (33.3) 42 (44.2) 114 (36.7) 0.63 (0.35-1.14) 0.87 (0.46-1.66)
Good 71 (32.9) 26 (27.4) 97 (31.2) 1.01 (0.54-1.90) 1.75 (0.82-3.74)
PrEP, Pre-exposure prophylaxis; HAART, Highly Active Anti-Retroviral Treatment; OR, Odds ratio; MLR-OR, Multiple variable Logistic Regression – Odds Ratio; CI,
Confidence Interval.
Boldface = p < 0.05.
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The main predictor of a negative attitude towards PrEP
prescription seems to be the scarce propensity to offer or
inform patients on PEP, and more in general to consider
ARV as a tool to prevent HIV transmission. Specialists
with a negative attitude believe behavioural interventions
to be more effective than PrEP, and feel uncomfortable
when prescribing drugs for new indications unless there is
clear evidence of benefit. The results of a survey
conducted at the conclusion of the 2012 International As-
sociation of Physicians in AIDS Care (IAPAC) meeting
“Controlling the HIV Epidemic with Antiretrovirals” are
in line with ours: over half of the summit attendees (56%)
chose funding as the largest barrier to implementation of
PrEP; most participants (70%) said that in their country
PrEP will be used only in selected cases, and mostly (91%)
following formal PrEP guidelines [23].
Even in our study most HIV specialists would welcome
guidelines on PrEP, and the start of a clinical trial where
their patients could be enrolled. Those with a negative at-
titude did not consider advisable that formal PrEP guide-
lines were issued (OR 0.30; 95% CI 0.13-0.66; p = 0.003).
When our survey was conducted only two guidance
documents were available, from the Centers for Disease
Control and Prevention (CDC) [24] and the British HIV
Association/British Association for Sexual Health and
HIV [25], mainly oriented to limit inappropriate pre-
scription, respectively, among MSM and outside the
context of a clinical research study.
Following FDA approval [26], and the availability of
conclusive data from studies of oral PrEP among hetero-
sexuals [6,7], the WHO released recommendations [27],
and the CDC issued a second interim guidelines targeted
to high-risk heterosexually active adults [28], both aimed
at guiding clinicians on providing PrEP outside of the
context of controlled clinical trials. So far, the European
Medicines Agency (EMA) has issued a Reflection paper
whose purpose is to highlight regulatory aspects regard-
ing the preclinical and clinical development of PrEP
[29].
Whether and how these documents might impact on
HIV specialists’ attitude and concerns and on the Euro-
pean and Italian settings, will need monitoring and fur-
ther reassessment.
Some of the barriers to PrEP prescription evidenced in
our study will probably be addressed by future trials and
open label studies [30].
Table 3 Perception of PrEP among HIV specialists according to their attitude towards PrEP prescription
Positive Negative Total OR (95% CI)
216 95 311
I am concerned that PrEP will not be 100% effective (N = 295) Agree 161 (78.9) 77 (84.6) 238 1
Disagree 43 (21.1) 14 (15.4) 57 1.47 (0.76-2.85)
I am concerned about the potential side effects of PrEP (N = 297) Agree 133 (64.9) 75 (81.5) 208 1
Disagree 72 (35.1) 17 (18.5) 89 2.39 (1.31-4.35)
I feel uncomfortable prescribing drugs for new indications unless
there is clear evidence of benefit (N = 293)
Agree 132 (65.0) 71 (78.9) 203 1
Disagree 71 (35.0) 19 (21.1) 90 2.01 (1.12-3.60)
I am concerned about a low adherence to PrEP* (N = 159) Agree 55 (59.8) 44 (65.7) 99 1
Disagree 37 (40.2) 23 (34.3) 60 1.29 (0.67-2.48)
I do not have time to engage in prevention counselling and PrEP
monitoring (N = 290)
Agree 22 (11.0) 7 (7.8) 29 1
Disagree 178 (89.0) 83 (92.2) 261 0.68 (0.28-1.66)
The use of PrEP will cause patients to engage in riskier behaviours
(N = 297)
Agree 145 (70.4) 73 (80.2) 218 1
Disagree 61 (29.6) 18 (19.8) 79 1.71 (0.94-3.10)
The provision of PrEP will result in an increase in sexually
transmitted disease incidence among patients (N = 296)
Agree 136 (66.7) 67 (72.8) 203 1
Disagree 68 (33.3) 25 (27.2) 93 1.34 (0.78-2.31)
Encourage access to testing and care for HIV infection are more
effective measures* (N = 160)
Agree 81 (87.1) 64 (95.5) 145 1
Disagree 12 (12.9) 3 (4.5) 15 3.16 (0.86-11.68)
Non-biomedical HIV prevention interventions (behavioural) are
more effective than PrEP (N = 290)
Agree 136 (67.7) 79 (88.8) 215 1
Disagree 65 (32.3) 10 (11.2) 75 3.78 (1.84-7.77)
Non-biomedical HIV prevention interventions (behavioural) are safer
than PrEP (N = 301)
Agree 183 (88.0) 84 (90.3) 267 1
Disagree 25 (12.0) 9 (9.7) 34 1.28 (0.57-2.85)
The use of PrEP will result in less frequent HIV testing among
patients (N = 299)
Agree 90 (43.7) 52 (55.9) 142 1
Disagree 116 (56.3) 41 (44.1) 157 1.63 (1.00-2.68)
PrEP is too costly (N = 295) Agree 159 (77.6) 78 (86.7) 237 1
Disagree 46 (22.4) 12 (13.3) 58 1.88 (0.94-3.75)
The use of antiretrovirals for prevention will select for, and
disseminate, antiretroviral drug resistance (N = 294)
Agree 135 (66.5) 68 (74.7) 203 1
Disagree 68 (33.5) 23 (25.3) 91 1.49 (0.85-2.60)
Denominators are reported for each item as non respondents were excluded at univariate analysis; percentages have been calculated on respondents.
* reference sample with different denominator (N = 172); PrEP, Pre-exposure prophylaxis; OR, Odds Ratio.
Boldface = p < 0.05.
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Other concerns, such as adherence, risk disinhibition
and the emergence of resistant strains, need further
evidence on wider populations and longer periods of
observation.
It is encouraging that HIV specialists, already loaded
with their current activities, strongly disagree with a lack
of time to engage in prevention counselling and clinical
monitoring of individuals on PrEP, differently from what
observed in other studies [20]. This is somehow consist-
ent with the high frequency with which PEP information
and treatment is provided in this group, and in accord-
ance with similar observations both in HIV specialists
and in generalists [15].
Training and providing continuing education to the
health workforce is another significant challenge. In our
survey, one third of interviewed HIV specialists reported a
poor knowledge of PrEP; also during the focus group, par-
ticipants reported unsatisfactory knowledge of PrEP trial
results. Even if we did not find a significant association
with the reported attitude towards PrEP prescription, bet-
ter knowledge has been associated with a higher willing-
ness to prescribe PrEP [13,15].
Our results may not apply to the whole population of
Italian HIV specialists.
First of all the participation rate was weak (40%), and no
data have been collected allowing to compare anonymous
respondents with non-respondents in order to characte-
rize the possible participation bias. Participants represent
a convenience sample, obtained using two different re-
cruitment methods (i.e. participation in HIV educational
courses versus participation in the online survey). The on-
line sample is composed only of members of the Italian
Society of Infectious Diseases, which collects most, but
not all, of the Italian infectious disease/HIV specialists.
Social desirability bias may have influenced the an-
swers to the questionnaires provided at the educational
HIV courses, although anonymous. This could explain at
least in part the significantly more positive attitude to-
wards PrEP prescription among respondent specialists
who participated in the HIV courses.
Conversely, previous studies have demonstrated that on-
line data collection has the potential to limit this bias and
result in more honest and accurate responses [31,32].
Therefore, we performed a sub-analysis only of the on-
line sample: the results we obtained were consistent with
those of the overall population.
Moreover, the questionnaire did not collect any personal
information about the physician (e.g. marital status, being
HIV positive or having close friends at risk of or with HIV
infection, religious faith or political beliefs, etc.) which
could influence specialists’ attitude toward PrEP in higher
proportions than the professional characteristics tested in
the model [33,34]; indeed, the multivariate model only ex-
plains 17.2% of the variance. Therefore, further studies are
needed to identify other predictors of PrEP prescription
apart from PEP provision.
Conclusion
In conclusion, the majority of respondent HIV specialists
would prescribe PrEP in specific situations. However,
conflicting attitudes appear evident, in line with the results
of a New England Journal of Medicine polling on PrEP, and
reflect uncertainties within the medical and public health
communities over which approaches will most effectively
control the global spread of HIV [35]. Whether additional
scientific evidence and enhanced knowledge could modify
attitudes needs monitoring and further investigation.
Identifying the populations at high risk for HIV infec-
tion and for whom PrEP use would be most effective, and
linking and retaining them in care, is one of the emerging
challenges. HIV specialists seem to be willing, pending fur-
ther evidence from ongoing studies and guidance from
normative bodies, to promote PrEP within multiple pre-
vention strategies among vulnerable populations.
Additional file
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